Another Method for Thawing Hematopoietic Stem Cells and its Impact in the Recovery of the Transplanted Hematological Patient  by Mancias-Guerra, Consuelo et al.
Abstracts / Biol Blood Marrow Transplant 19 (2013) S342eS354 S349than targeting either alone. Erythropoietin-producing hepa-
tocellular carcinoma-A2 (EphA2)-speciﬁc CAR T cells were
used to target the A549 tumor cells. EphA2-speciﬁc T cells
when administered together with FAP-speciﬁc T cells, resul-
ted in a signiﬁcant decrease in tumor growth and increased
survival compared tomice that receivedeither EphA2-or FAP-
speciﬁc T cells alone. Our study underscores the value of co-
targeting both CAFs and cancer cells to increase the beneﬁts of
T-cell immunotherapy for solid tumors.
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Fully Automated Clinical-Scale Separation of CD133+ Cells
From Bone Marrow Aspirate
Mike Essl, Juliane Stuth, Volker Huppert, Gerd Steffens,
Petra Held, Dirk Balshuesemann. Miltenyi Biotec GmbH
There is a growing interest in CD133 antigen expressing stem
cell in the ﬁeld of regenerative medicine such as cardiovas-
cular, peripheral artery, and liver disease. Investigators in
particular concentrate on bone marrow-derived stem cells
for these applications. Today the clinical scale enrichment of
CD133+ cells has to be performed as a complex procedure
involving numerous manual handling steps.
We have developed a fully automated clinical scale process
withinaclosedsterile systemtopurifyCD133+cells fromhuman
bone marrow aspirates. In this context, erythrocyte reduction,
generation of autologous plasma, labeling time and the condi-
tions for immunomagnetic separationwere optimized.
To determine the process performance, CD133+ cells were
separated from human bonemarrow aspirates with an initial
volume of about 60 mL (n¼10). We performed colony-
forming unit (CFU) assays, which allowed us to evaluate the
differentiation potential of the enriched cells.
The total processing time was reduced from about 4.5 h
(previous manual process) to 2.5 h. The number of enriched
CD133+ cells was 7.9x105 (range: 3.7x105 to 1.9x106). The
average yield was 47% and the average viability of the sepa-
rated CD133+ cells achieved 90% (range: 69.9% to 96.9%). The
depletion of CD133 negative cells was >99.9%. CFU assays
perfomed after the fully automated enrichment process
showed that the CD133+ cell fraction contained primitive and
multipotentprogenitorcells, suchasCFU-GEMMandCFU-GM.
The cell separation system described provides a safe and easy
way to purify CD133+ cells from bone marrow aspirates
within 2.5 h without any intermediate manual steps. The cell
preparation in a closed sterile system facilitates a fast and
robust enrichment of CD133+ cells. The cells are eluted in
a small volume (6 mL) and can be used directly for further
applications according to requirements e.g. for use in
regenerative medicine.
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Promotion of Wound Healing by Cord Blood Derived
Unrestricted Somatic Stem Cells (USSCs) in a Murine
Wound Healing Model and Analysis on Their
Bio-Distribution by In Vivo Bioluminescent Imaging (BLI)
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Carmella van de Ven 1, Angela Christiano 2,
Mitchell S. Cairo 1,3,4,5,6. 1 Pediatrics, New York Medical College,
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Center, New York, NY; 3Microbiology and Immunology,
New York Medical College, Valhalla, NY; 4 Pathology, New York
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Background: Delayed healing of skin wounds is a major
morbidity. Repeated wounding is characteristic in patients
with recessive dystrophic epidermolysis bullosa (RDEB),
caused bymutations in COL7A1 gene. Stem cell therapy offers
an option in treating this disease (Kiru/Cairo et al. PNAS,
2011). Recently, cord blood (CB) derived pluripotent stem
cells, USSCs, have been applied in several animal models of
degenerative diseases with beneﬁcial outcomes.
Goal: To determine the potential of USSCs in the treatment of
RDEB and its associated wounding phenotype.
Method: CB-USSCs were characterized for genetic and
functional properties. Their in vivo functions were evaluated
in a murine full-thickness excisional wound healing model
and by bioluminescent imaging (BLI), using USSCs modiﬁed
with a luciferase reporter gene.
Results: CB-USSCs share several embryonic stem cell prop-
erties and could be induced to express hallmark genes of
keratinocyte differentiation. USSCs constitutively express
Col7A1, supporting their therapeutic potential in the treat-
ment of patients with RDEB. In the wounding model, a single
USSC intradermal injection promoted epithelialization and
facilitated formation and remodeling of epidermis, accom-
panied by a signiﬁcantly accelerated rate of wound healing
on days 6-10 post wounding (F(1,168)¼50.8 P< .01). In vivo BLI
revealed speciﬁc migration of USSCs from a distant intra-
dermal injection site toward the wound, as well as following
systemic injection. Temporal quantiﬁcation on the total
bioluminescence indicated an overall 59.9% signal loss over 3
days followed by a 95.06% loss at 1 week. The biolumines-
cence in the area of wound was then maintained atw0.5-1%
level till the end of the experiment (3 month). USSCs express
several chemokine receptors that may mediate their migra-
tion to the wound, including CXCR4 (for SDF1), CCR7 (for
CCL21) and PDGFRa (for HMGB1). In vitro chemotaxis assays
indicated that SDF-1 signiﬁcantly enhanced USSC migration
at a concentration of 100ng/ml, while neither CCL21 nor
HMGB1 showed signiﬁcance even at a concentration of 10mg/
ml. The effects of such chemokine/receptor interactions on
USSC recruitment in vivo are now being investigated.
Conclusion: These results suggest signiﬁcant beneﬁcial
effects of CB-USSCs on wound healing and raised the possi-
bility of USSC's therapeutic beneiﬁt in the treatment of
patients with RDEB.
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and its Impact in the Recovery of the Transplanted
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Guillermo Cayetano Aguirre-Fernandez Jr. 1,
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Introduction: There are several hematopoietic-stem cells
(HSCs) thawing methods for bone marrow reconstitution.
They intend to avoid cell death and patient's side effects due
to the dimethyl sulfoxide (DMSO). We propose another
thawing method that diminishes cell death and therefore
a more rapid hematological recovery.
Material and Methods: The standard thawing-removing
DMSO method for cord blood units was described by
Table 1
Patient's demographic data
Global Method 1 Method 2 P
Total (n) 26 13 13
Transplant (n) .43
Autologous 12 5 7
Allogeneic 14 8 6
Receptor age (years) .75
Median (range) 26 (3-56) 27 (5-55) 25 (3-56)
Table 2
Overall results in the study
Global Rubinstein's New Method P
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increase more than 10 fold the dilution of cryopreserved
HSCs in the standardwashing solution (5% albumin + dextran
40). Methods 1 and 2 were compared to determine viability
by means of total-nucleated-cell (TNC) count by trypan blue
and ﬂow cytometry at the time of collection, cryopreserva-
tion, thawing, and after removing the DMSO, as well as the
patient's day of engraftment.
Results: Results are shown in Tables 1 and 2.
Conclusions: A greater dilution of cryopreserved HSCs in the
washing solution, as a new thawing method, may decrease
cell death; therefore a greater number of HSCs will be
infused to the patient. Studies with a larger number of
thawing procedures are needed to make this assertion.Figure 1. Viability loss
Figure 2. Neutrophil engrafment
Figure 3. Platelel engrafmentMethod
Viability before
thawing.
Mean (SD)
97.28% (6.55) 99.01% (1.08) 95.56% (9.04) .30
Viability after
thawing.
Mean (SD)
78.92% (11.69) 75.46% (12.5) 82.39% (10.12) .15
Viability loss.
Mean (SD)
18.36% (12.11) 23.55% (12.74) 13.18% (9.21) .02
Engrafment days
>20,000
Platelets.
Median (range)
11 (6-23) 11 (6-23) 11 (7-19) .60
Engrafment
days >500
Neutrophils.
Median (range)
13.5 (6-28) 13 (6-28) 14 (9-17) .30483
Dissection of the Human Multipotent Adult Progenitor
Cell (MAPC) Secretome by Proteomic Analysis
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University; Wouter Van't Hof, Athersys, Inc., Cleveland, OH;
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Science University; 3 Regenesis, Inc; 4 Regenesys, Inc;
5 Regenerative Medicine, Athersys, Inc, Cleveland, OH; 6Oregon
Health & Science University
Multipotent adult progenitor cells (MAPC; Multistem) are
adult adherent stromal stem cells currently being assessed
in acute GVHD clinical trials with demonstrated immuno-
modulatory capabilities and the potential to ameliorate
detrimental autoimmune and inﬂammation-related
processes. Our previous studies documented that MAPC
secrete factors that play a role in regulating T cell activity.
Here we expand our studies using a proteomics approach to
characterize and quantify MAPC secretome components
secreted over 72 hours in vitro under steady-state condi-
tions and in the presence of inﬂammatory triggers IFN-
gamma and LPS, or a tolerogenic CD74 ligand, RTL1000.
MAPC differentially respond to each of the tested stimuli,
secreting molecules that regulate the biological activity of
the extra-cellular matrix (ECM), including proteins that
comprise the ECM itself, proteins that regulate its
construction/de-construction, and proteins that serve to
attach and de-attach growth factors from ECM components
for redistribution upon appropriate stimulation. MAPC
secrete a wide array of proteases, some detectable in their
zymogen forms, as well as protease inhibitors that serve to
poise the ECM in a state of repose, ready to respond
